Gastroprotective efficacy and safety of single-tablet ibuprofen/famotidine vs ibuprofen in older persons

Abstract

(2015) Gastroprotective efficacy and safety of single-tablet ibuprofen/famotidine vs ibuprofen in older persons, The Physician and Sportsmedicine, 43:3, 193-199, DOI: 10.1080/00913847.2015 Objectives: A combination tablet of ibuprofen 800 mg and famotidine 26.6 mg given three times daily is effective for the treatment of rheumatoid arthritis and osteoarthritis and decreases the risk of developing upper gastrointestinal (GI) ulcers. This analysis evaluated the gastroprotective efficacy and safety of the single-tablet combination of ibuprofen/famotidine compared with ibuprofen alone on the basis of age and the presence of one or more risk factors for development of upper GI ulcer. Methods: Pooled data from the 24-week, randomized, double-blind, parallel-group REDUCE-1 and REDUCE-2 trials were used. Endoscopies were performed in patients aged 40-80 years. The proportion of patients who developed ‡1 upper GI ulcer during treatment with ibuprofen/famotidine versus ibuprofen alone stratified on the basis of age (<60 or ‡60 years) was evaluated. Further, analyses were performed on additional risk factors for ulcer development. Results: Gastroprotective efficacy of the combination was not affected by age. Pooled results demonstrated statistically significantly fewer upper GI (10.0 vs 19.5%, p < 0.0001), gastric (8.9 vs 16.8%, p = 0.0004), and duodenal ulcers (1.1 vs 5.4%, p < 0.0001) in patients <60 years treated with ibuprofen/famotidine versus ibuprofen alone compared with 12.9 vs 26.6% (p = 0.0002), 11.9 vs 23.4% (p = 0.0011), and 1.0 vs 4.5% (p = 0.0096), respectively, in patients ‡60 years. The ibuprofen/famotidine combination provided nearly 51 and 59% reduction in the risk of developing a GI ulcer in patients <60 years and ‡60 of age, respectively. Efficacy was maintained in the presence of additional risk factors, as well. Conclusions: These results indicate that the fixed-combination of ibuprofen/famotidine provides gastroprotection in those of older age, with or without additional risk factors for the development of upper GI ulcers, as compared with ibuprofen alone. US National Institutes of Health registry, http://www.clinicaltrials.gov, NCT00450658 and NCT00450216.

Ibuprofeno: ¿fármaco seguro?

“…La combinación de ibuprofeno/famotidina proporcionó una reducción de casi 51 y 59% en el riesgo de desarrollar una úlcera gastrointestinal alta (gástrica y duodenal) en pacientes menores de 60 años y mayores de 60 años de edad, respectivamente (25).…”

Çocuklarda antipiretik olarak ibuprofen doğru seçenek mi?

“…Tedavi ilk hedef intravasküler volüm azalmasına bağlı hemorajik şok tablosundan korumaktır. Uzun süre ibuprofen kullanımı zorunlu kronik kas-iskelet ağrısı olan çocuklarda, gastrointestinal sistem yan etkilerini önlemek için histamin -2 reseptör antagonisti famotidin veya nizatidin ile kombinasyonunun güvenilir ve başarılı olduğu ratlarda ve insanlarda bildirilmiştir 1,2,4 . Aynı zamanda proton pompa inhibitörleri (lansoprazol, pantoprazol ve esomeprazol gibi), özellikle son yıllarda sık olarak kullanılmakta ve hem akut hem de kronik kullanımda etkin ve güvenilir olduğu gösterilmiştir 5 .…”

Merging konjac glucomannan with other copolymeric hydrogels as a cutting-edge liquid raft system for dual delivery of etoricoxib and famotidine

“…Methods to reduce the drug’s GIT side effects like the incorporation of antacids (H 2 blockers) (Birk & Myers, 2009 ), and designing the floating raft systems (RS) (in-situ gelling approach) were proposed. Clinical evidence has proven that famotidine in combination with NSAIDs can be used to minimize the GIT side effects resulting from the frequent use of analgesics (Birk & Myers, 2009 ; Bello, 2012 ; Deeks, 2013 ; Sugano, 2013 ; Bello et al., 2015 ; Taha, 2015 ). Famotidine is a selective H2 receptor antagonist that is used to treat GIT ulcers by inhibiting both the concentration and volume of gastric acid secretions (Bello, 2012 ).…”